(±) -BI-D

• Description:

  (±) -BI-D is a potent ALLINI (allosteric integrase inhibitor) . (±) -BI-D binds integrase at the LEDGF/p75 binding site. (±) -BI-D inhibits HIV-Luc infection in cells (IC50: 0.16 μM in Psip1 knockout E9 mouse embryonic fibroblasts, 2.9 μM in wild-type E9 mouse embryonic fibroblasts) [1][2].

• UNSPSC:

  12352005

• Target:

  HIV; HIV Integrase

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; Metabolic Enzyme/Protease

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/__plusmn__-BI-D.html

• Purity:

  98.06

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  OC(C(OC(C)(C)C)C1=C(C(C=CC=C2)=C2N=C1C)C3=CC(CCCO4)=C4C=C3)=O

• Molecular Formula:

  C25H27NO4

• Molecular Weight:

  405.49

• References & Citations:

  [1]Wang H, et al. HRP2 determines the efficiency and specificity of HIV-1 integration in LEDGF/p75 knockout cells but does not contribute to the antiviral activity of a potent LEDGF/p75-binding site integrase inhibitor. Nucleic Acids Res. 2012 Dec;40 (22) :11518-30.|[2]Fader LD, et al. Minimizing the Contribution of Enterohepatic Recirculation to Clearance in Rat for the NCINI Class of Inhibitors of HIV. ACS Med Chem Lett. 2014 Apr 16;5 (6) :711-6.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [1416258-16-6]